New antisense oligonucleotide therapies reach first base in ALS

Nat Med. 2022 Jan;28(1):25-27. doi: 10.1038/s41591-021-01629-7.

Authors

Elia R Lopez¹, William F Borschel¹, Bryan J Traynor^{2

3}

Affiliations

¹ Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
² Therapeutic Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA. traynorb@mail.nih.gov.
³ Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. traynorb@mail.nih.gov.

PMID: 35075291
DOI: 10.1038/s41591-021-01629-7

No abstract available

Publication types

Research Support, N.I.H., Intramural
Comment

MeSH terms

Amyotrophic Lateral Sclerosis* / drug therapy
Amyotrophic Lateral Sclerosis* / genetics
Frontotemporal Dementia*
Humans
Oligonucleotides, Antisense / therapeutic use

Substances

Oligonucleotides, Antisense

Grants and funding

Z01 AG000949/ImNIH/Intramural NIH HHS/United States